Company
Melbourne, VIC
Every investor coverage indicates participated in a round Walter and Eliza Hall Institute raised.
Companies Walter and Eliza Hall Institute acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Walter and Eliza Hall Institute. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile tracing Sara Prickett's path from UK labs to co-founding Aravax, the peanut-allergy biotech Brandon Capital backed, as its Phase II trial nears readout in mid-2026.
A profile of Brandon Capital partner Chris Smith, tracing his path from immunology research and a Cambridge postdoc into biotech investing, with resilience lessons drawn from equestrian sport and companies Aravax and ENA Respiratory.
Profile of Australian biotech startup Proxima Bio, covering its founding, an early MRFF grant through the CUREator program, Brandon Capital's guidance, and a later larger investment that grew the team.
Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.
A 2007 announcement that Australian biotech ChemGenex Pharmaceuticals appointed former Amgen executive Dr George Morstyn to its board, with CEO Greg Collier citing his oncology development and commercialisation expertise.